We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

11 hedge funds and large institutions have $2.9M invested in Moleculin Biotech in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital inflows, than outflows

Capital inflows: $443K | Capital outflows: $351K

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.24% less ownership

Funds ownership: 10.17% → 8.94% (-1.2%)

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$204K
2
Raymond James Financial Services Advisors
Raymond James Financial Services Advisors
Florida
+$68.1K
3
Two Sigma Securities
Two Sigma Securities
New York
+$68.1K
4
Citadel Advisors
Citadel Advisors
Florida
+$34.1K
5
UBS Group
UBS Group
Switzerland
+$34.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$137K
2
Millennium Management
Millennium Management
New York
-$88K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$65K
4
Morgan Stanley
Morgan Stanley
New York
-$32K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$16K

MBRX Hedge Fund Activity: Q1 2020 in Review

11 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2020, worth a combined $2.9M — down 32% from $4.26M a quarter earlier.

Fund positioning in MBRX was balanced in Q1 2020: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $204K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $137K sold.

  • 11 institutional investors held Moleculin Biotech (MBRX) as of Q1 2020, unchanged from Q4 2019.
  • Funds reported $2.9M of Moleculin Biotech stock for Q1 2020, down 32% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q1 2020 and 4 closed out, a net change of 0 holders.
  • The largest Moleculin Biotech buyer in Q1 2020 was Renaissance Technologies, an estimated $204K added.
  • The largest Moleculin Biotech seller in Q1 2020 was Susquehanna International Group, an estimated $137K sold.

Based on aggregated 13F filings for Q1 2020.